Maravai LifeSciences Holdings, Inc.
General ticker "MRVI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $869.7M (TTM average)
Maravai LifeSciences Holdings, Inc. follows the US Stock Market performance with the rate: 51.6%.
Estimated limits based on current volatility of 5.7%: low 7.14$, high 8.00$
Factors to consider:
- Total employees count: 435 (-23.7%) as of 2025
- North America accounted for 48.8% of revenue in the fiscal year ended 2023-12-31
- Top business risk factors: Market demand decline, Regulatory and compliance, Technology reliability issues, Market competition, Supply chain disruptions
- Current price 14.3% above estimated high
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.63$, 6.46$]
- 2026-12-31 to 2027-12-31 estimated range: [2.62$, 6.32$]
Financial Metrics affecting the MRVI estimates:
- Positive: with PPE of -11.8 at the end of fiscal year the price was neutral
- Negative: Operating cash flow per share per price, % of -11.97 <= 0.28
- Positive: -4.23 < Operating profit margin, % of -3.50
- Positive: -14.39 < Investing cash flow per share per price, % of -6.53
- Positive: 18.97 < Shareholder equity ratio, % of 27.56 <= 42.26
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
Short-term MRVI quotes
Long-term MRVI plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $288.94MM | $259.19MM | $185.74MM |
| Operating Expenses | $320.59MM | $494.80MM | $192.48MM |
| Operating Income | $-31.65MM | $-235.62MM | $-6.74MM |
| Non-Operating Income | $649.38MM | $-25.86MM | $-228.24MM |
| Interest Expense | $45.89MM | $47.70MM | $26.99MM |
| R&D Expense | $17.28MM | $19.22MM | $17.40MM |
| Income(Loss) | $617.74MM | $-261.48MM | $-234.97MM |
| Taxes | $756.11MM | $-1.86MM | $-4.21MM |
| Net Income(Loss)* | $-119.03MM | $-144.85MM | $-130.77MM |
| Stockholders Equity | $416.75MM | $325.29MM | $212.38MM |
| Inventory | $51.40MM | $50.08MM | $40.49MM |
| Assets | $1,487.45MM | $1,008.24MM | $770.58MM |
| Operating Cash Flow | $126.22MM | $7.46MM | $-57.57MM |
| Capital expenditure | $65.55MM | $29.66MM | $13.15MM |
| Investing Cash Flow | $-122.31MM | $-24.32MM | $-31.41MM |
| Financing Cash Flow | $-61.09MM | $-235.71MM | $-16.50MM |
| Earnings Per Share** | $-0.90 | $-1.05 | $-0.90 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.